Company

Spear Bio, Inc.

Spear Bio develops ultrasensitive immunodiagnostic and proteomics technologies.

About

Founded in 2021 and based in Woburn, US, Spear Bio develops an ultrasensitive immunodiagnostics and proteomics platform using successive proximity extension amplification reaction (SPEAR). Its products include NAB-Sure™, an assay for measuring SARS-Cov-2 neutralizing antibodies, and immunoassays for low-abundance proteins. In July 2024, it raised USD 45 million in Series A funding co-led by Foresite Capital and Bio-Techne Corporation, with participation from Maverick Ventures, Yonghua Capital, and CDH Investments.

2Funding rounds

4Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in